Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
- Development stage
- Unknown
- Lead developer
- Wang Xiaoyan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug combination is a bismuth-containing quadruple therapy (BQT) regimen specifically designed for the eradication of *Helicobacter pylori* infection. It consists of four distinct components: esomeprazole, a proton pump inhibitor (PPI) that suppresses gastric acid secretion; colloidal bismuth tartrate, which provides mucosal protection and exerts direct bactericidal effects against the pathogen; and two antibiotics, amoxicillin (a beta-lactam) and doxycycline (a tetracycline), which inhibit bacterial cell wall and protein synthesis, respectively. This specific regimen is being evaluated in clinical trials led by investigator Wang Xiaoyan to compare its efficacy, safety, and patient compliance against vonoprazan-based therapies. The combination is particularly relevant in clinical settings where resistance to clarithromycin or metronidazole is prevalent, as it utilizes antibiotics with lower resistance rates in many populations.
- Other names
- esomeprazole-bismuth quadruple therapyEBAD
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)Bacterial Ribosome
Beyond the preview
Go deeper on esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline.